About Our Lab
Cancer is a diverse and heterogeneous disease, hence one therapy will not be uniformly beneficial to all patients. To dissect heterogeneity at the molecular level, we employ multi-omics analysis on data generated from patient tumors. We implement integrated bioinformatic approaches to understand the role of mutations, structural variations, gene expressions, genomic alterations, proteomic and phospho-proteomic signatures in promoting cancer or driving drug resistance. Our research lab focuses on improving cancer diagnosis, treatment and survival by employing data science in precision medicine.

Lab News
- Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer
- The importance of a biomarker-directed approach in triple-negative breast cancer (video)
- LIG1 deletion predicts chemotherapy resistance in triple-negative breast cancer (video)
- Treatments for HR+ postmenopausal breast cancer (video)
- OCCPR Webinar: Translational Discovery and Validation Using Multi-omics Data from ER+ Breast Tumors (video)
- Meenakshi Anurag on Breast Cancer: New Data on Combining Anastrozole and Fulvestrant